{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2023"],"condition":["Colorectal Cancer","Colorectal Neoplasms","Solid Tumors"],"disease":["Colorectal Cancer","Colorectal Neoplasms","Solid Tumors"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/8638"],"location":["United States"],"study_start_month":["4"],"keyword":["SNDX-5613","Revumenib","Menin"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Evaluation of SNDX-5613 in Participants With Colorectal Cancer and Other Solid Tumors","description":"This study will evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of SNDX-5613 in participants with colorectal cancer (CRC) or other solid tumors who have failed at least 1 prior line of therapy.","dates":{"creation":"2023-04-15"},"accession":"8638","cross_references":{"ClinicalTrials___gov":["NCT05731947"]}}